Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 5032 | 3.1 |
09:36 ET | 1260 | 3.12 |
09:38 ET | 3967 | 3.16 |
09:39 ET | 5360 | 3.165 |
09:41 ET | 3955 | 3.135 |
09:43 ET | 870 | 3.14 |
09:45 ET | 3192 | 3.12 |
09:48 ET | 1512 | 3.11 |
09:50 ET | 1686 | 3.095 |
09:52 ET | 1430 | 3.09 |
09:54 ET | 227 | 3.095 |
09:56 ET | 1088 | 3.09 |
09:57 ET | 8954 | 3.08 |
09:59 ET | 1192 | 3.08 |
10:01 ET | 1896 | 3.095 |
10:03 ET | 563 | 3.1 |
10:06 ET | 450 | 3.1 |
10:08 ET | 600 | 3.095 |
10:10 ET | 1199 | 3.085 |
10:12 ET | 6626 | 3.1 |
10:14 ET | 200 | 3.11 |
10:15 ET | 2562 | 3.1046 |
10:17 ET | 300 | 3.105 |
10:19 ET | 300 | 3.1 |
10:21 ET | 3632 | 3.095 |
10:24 ET | 200 | 3.09 |
10:26 ET | 466 | 3.09 |
10:28 ET | 4138 | 3.105 |
10:30 ET | 5988 | 3.105 |
10:32 ET | 1105 | 3.105 |
10:33 ET | 8669 | 3.08 |
10:35 ET | 2498 | 3.075 |
10:37 ET | 300 | 3.07 |
10:39 ET | 4187 | 3.085 |
10:42 ET | 1300 | 3.0899 |
10:44 ET | 398 | 3.085 |
10:46 ET | 3717 | 3.07 |
10:48 ET | 2912 | 3.085 |
10:50 ET | 398 | 3.085 |
10:51 ET | 200 | 3.085 |
10:53 ET | 111 | 3.085 |
10:57 ET | 284 | 3.085 |
11:00 ET | 100 | 3.09 |
11:02 ET | 200 | 3.09 |
11:04 ET | 1394 | 3.09 |
11:06 ET | 7897 | 3.085 |
11:08 ET | 1032 | 3.09 |
11:09 ET | 1441 | 3.085 |
11:11 ET | 3797 | 3.09 |
11:13 ET | 493 | 3.095 |
11:15 ET | 2598 | 3.105 |
11:18 ET | 249 | 3.1013 |
11:20 ET | 3354 | 3.09 |
11:22 ET | 443 | 3.095 |
11:24 ET | 1200 | 3.097 |
11:26 ET | 300 | 3.095 |
11:27 ET | 100 | 3.09 |
11:29 ET | 100 | 3.1 |
11:31 ET | 200 | 3.1 |
11:33 ET | 10807 | 3.095 |
11:36 ET | 5104 | 3.085 |
11:38 ET | 345 | 3.085 |
11:40 ET | 200 | 3.085 |
11:42 ET | 300 | 3.085 |
11:44 ET | 4405 | 3.07 |
11:45 ET | 3255 | 3.085 |
11:47 ET | 100 | 3.08 |
11:49 ET | 400 | 3.085 |
11:51 ET | 9526 | 3.08 |
11:54 ET | 300 | 3.075 |
11:56 ET | 151 | 3.075 |
11:58 ET | 200 | 3.07 |
12:00 ET | 400 | 3.075 |
12:02 ET | 200 | 3.07 |
12:03 ET | 3067 | 3.085 |
12:05 ET | 400 | 3.09 |
12:07 ET | 845 | 3.09 |
12:09 ET | 460 | 3.0863 |
12:12 ET | 961 | 3.095 |
12:14 ET | 100 | 3.095 |
12:16 ET | 100 | 3.09 |
12:18 ET | 367 | 3.095 |
12:20 ET | 5100 | 3.095 |
12:21 ET | 677 | 3.095 |
12:23 ET | 13746 | 3.1 |
12:25 ET | 2300 | 3.095 |
12:27 ET | 374 | 3.095 |
12:30 ET | 1800 | 3.095 |
12:32 ET | 600 | 3.09 |
12:34 ET | 458 | 3.09 |
12:36 ET | 200 | 3.095 |
12:38 ET | 400 | 3.09 |
12:39 ET | 300 | 3.1 |
12:41 ET | 533 | 3.095 |
12:43 ET | 2000 | 3.095 |
12:45 ET | 6599 | 3.085 |
12:48 ET | 300 | 3.0888 |
12:50 ET | 349 | 3.08 |
12:52 ET | 3707 | 3.09 |
12:54 ET | 262 | 3.085 |
12:56 ET | 300 | 3.09 |
12:57 ET | 354 | 3.09 |
12:59 ET | 9425 | 3.08 |
01:01 ET | 400 | 3.08 |
01:03 ET | 539 | 3.08 |
01:06 ET | 4170 | 3.08 |
01:08 ET | 400 | 3.07 |
01:10 ET | 359 | 3.07 |
01:12 ET | 617 | 3.075 |
01:14 ET | 600 | 3.07 |
01:15 ET | 5508 | 3.09 |
01:17 ET | 858 | 3.1 |
01:19 ET | 100 | 3.1 |
01:21 ET | 340 | 3.095 |
01:26 ET | 229 | 3.0971 |
01:28 ET | 1457 | 3.1 |
01:30 ET | 5046 | 3.1 |
01:32 ET | 421 | 3.095 |
01:33 ET | 1346 | 3.095 |
01:35 ET | 200 | 3.1 |
01:37 ET | 1100 | 3.0939 |
01:39 ET | 2869 | 3.09 |
01:42 ET | 730 | 3.1 |
01:44 ET | 200 | 3.1 |
01:46 ET | 400 | 3.09 |
01:48 ET | 700 | 3.09 |
01:50 ET | 1716 | 3.09 |
01:51 ET | 200 | 3.1 |
01:53 ET | 374 | 3.1 |
01:55 ET | 1584 | 3.09 |
01:57 ET | 200 | 3.09 |
02:02 ET | 7592 | 3.085 |
02:04 ET | 7582 | 3.09 |
02:06 ET | 368 | 3.094 |
02:08 ET | 200 | 3.095 |
02:09 ET | 200 | 3.095 |
02:11 ET | 438 | 3.095 |
02:13 ET | 139469 | 3.075 |
02:20 ET | 774 | 3.075 |
02:22 ET | 3891 | 3.07 |
02:24 ET | 6979 | 3.06 |
02:26 ET | 1200 | 3.06 |
02:27 ET | 100 | 3.06 |
02:29 ET | 3860 | 3.065 |
02:31 ET | 951 | 3.065 |
02:33 ET | 8651 | 3.05 |
02:36 ET | 1909 | 3.05 |
02:38 ET | 358 | 3.045 |
02:40 ET | 290 | 3.04 |
02:42 ET | 6307 | 3.03 |
02:44 ET | 373 | 3.03 |
02:45 ET | 356 | 3.03 |
02:47 ET | 2634 | 3.035 |
02:49 ET | 2442 | 3.03 |
02:51 ET | 500 | 3.035 |
02:54 ET | 705 | 3.03 |
02:56 ET | 500 | 3.03 |
02:58 ET | 945 | 3.03 |
03:00 ET | 1032 | 3.035 |
03:02 ET | 600 | 3.035 |
03:03 ET | 5756 | 3.025 |
03:05 ET | 421 | 3.02 |
03:07 ET | 400 | 3.025 |
03:09 ET | 480 | 3.02 |
03:12 ET | 900 | 3.025 |
03:14 ET | 1500 | 3.025 |
03:16 ET | 1200 | 3.025 |
03:18 ET | 10829 | 3.045 |
03:20 ET | 300 | 3.045 |
03:21 ET | 500 | 3.045 |
03:23 ET | 6022 | 3.05 |
03:25 ET | 500 | 3.045 |
03:27 ET | 700 | 3.045 |
03:30 ET | 22476 | 3.065 |
03:32 ET | 8944 | 3.055 |
03:34 ET | 12307 | 3.065 |
03:36 ET | 5251 | 3.055 |
03:38 ET | 3110 | 3.07 |
03:39 ET | 2487 | 3.0613 |
03:41 ET | 500 | 3.07 |
03:43 ET | 1716 | 3.06 |
03:45 ET | 5870 | 3.08 |
03:48 ET | 3250 | 3.075 |
03:50 ET | 13009 | 3.065 |
03:52 ET | 4993 | 3.07 |
03:54 ET | 2350 | 3.08 |
03:56 ET | 13905 | 3.09 |
03:57 ET | 23326 | 3.09 |
03:59 ET | 18191 | 3.08 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 761.3M | -9.8x | --- |
Viridian Therapeutics Inc | 772.9M | -2.7x | --- |
ProKidney Corp | 780.8M | -5.9x | --- |
Praxis Precision Medicines Inc | 754.1M | -2.8x | --- |
Cogent Biosciences Inc | 785.9M | -3.3x | --- |
Longboard Pharmaceuticals Inc | 730.9M | -8.3x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $761.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.